Latest research on MK-0518

Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. [Wikipedia]

MK-0518 side effects

The dosage of raltegravir (Isentress, Merck & Co., Inc., Whitehouse Station, NJ, USA) was determined based on the human therapeutic dosing (400 mg twice daily, orally), for the average human body weight of 60 kg [22] and multiplying by 10, because it has been described that experimental animals are generally less vulnerable than humans, by a factor of approximately 10 [23]. [source, 2014]